

Newborn Screening Quality Assurance Program

PROFICIENCY TESTING

Toxoplasma Quarterly Report

Volume 9, No. 3

August 2013

INTRODUCTION

This report is the quarterly summary of all data reported within the specified data-reporting period for Quarter 3, 2013. The attached tables provide the certification profiles for the distributed specimens, the verification of your reported data, the statistical analysis of the quantitative data, and the frequency distribution summaries for expected interpretations. We distribute this PT report to all participants, state laboratory directors, and program colleagues by request.

On July 8, 2013, a panel of five unknown dried-blood-spot (DBS) specimens prepared from human serum positive for exposure to *Toxoplasma gondii* was distributed to two laboratories in the United States and six laboratories in other countries. This panel was prepared from serum samples positive for Toxoplasma IgG and IgM purchased from SeraCare (Medford, Massachusetts) and from human serum positive for exposure to *Toxoplasma gondii* from a CDC specimen bank. All serum samples were mixed with washed red blood cells and the final hematocrit was adjusted to 50%.

PARTICIPANTS' RESULTS

We processed data from eight participants. Laboratories were asked to report IgM screening results in Absorbance (OD) or other units. In the statistical summary analysis, we did not include data that were outside the 99% confidence interval.

Four laboratories reported using an enzyme immunoassay method; two used a fluorometric enzyme immunoassay; and two used a multiplexed platform. The expected anti-Toxoplasma IgM values were based on CDC assayed values. Overall statistics from the enzyme immunoassay methods are summarized in Tables 1a – 1c. The frequency distribution of participants' interpretations for screening results is shown in

Table 2 and the frequency distribution of participants' interpretations for confirmatory results is shown in Table 3.

Expected interpretations (qualitative assessments) may differ by participant because of specific assessment practices. Overall, participants reported two false-negative interpretations and one false-positive interpretations. Laboratory results were evaluated on the basis of the final answers provided (screening only or confirmatory results). The mean cutoff for the enzyme immunoassay methods was 0.238, with a range from 0.1 to 0.383 OD; the mean cutoff for the multiplexed methods was 5.0 UA/mL (arbitrary units/mL serum); and the mean cutoff for the fluorescence immunoassay methods was 120 EIU (enzyme immunoassay units/mL serum).

Participants were asked to confirm specimens that screened above their cutoff for sorting test results that were Toxoplasma-antibody reactive from those that were Toxoplasma-antibody non-reactive. Three laboratories provided confirmatory results using an EIA for IgG or a multiplexed platform for IgG.

The Newborn Screening Quality Assurance Program will ship next quarter's Anti-Toxoplasma antibodies PT specimens on October 7, 2013. ❖

CDC/APHL

Direct inquiries to:
Centers for Disease Control and Prevention (CDC)
4770 Buford Highway, NE, MS/F43
Atlanta, GA 30341-3724

This program is cosponsored by the Centers for Disease Control and Prevention (CDC)
and the Association of Public Health Laboratories (APHL).

Phone: 770-488-7945
FAX: 770-488-4255
E-mail: JMei@cdc.gov

Editor: Joanne Mei
Production: Irene Williams
Connie Singleton



NEWBORN SCREENING QUALITY ASSURANCE PROGRAM

ANTI-TOXOPLASMA Antibodies

Quarter 3 – AUGUST 2013

OVERALL STATISTICS – IgM

Table 1a. Screening Results – Enzyme Immunoassay Methods

| Specimen | N | Outliers* | Mean (OD)** | UL (95%) | LL (95%) |
|----------|---|-----------|-------------|----------|----------|
| 313T1 | 4 | 0 | 0.214 | 0.317 | 0.111 |
| 313T2 | 4 | 0 | 0.600 | 1.200 | 0.001 |
| 313T3 | 4 | 0 | 0.060 | 0.138 | 0.000 |
| 313T4 | 4 | 0 | 0.063 | 0.137 | 0.000 |
| 313T5 | 4 | 0 | 0.074 | 0.169 | 0.000 |

* Outliers are not included in N UL = upper limit LL = lower limit

Table 1b. Screening Results – Multiplexed Immunoassay Methods

| Specimen | N | Outliers* | Mean (UA/mL)*** | UL (95%) | LL (95%) |
|----------|---|-----------|-----------------|----------|----------|
| 313T1 | 2 | 0 | 301.5 | 333.4 | 269.6 |
| 313T2 | 2 | 0 | 159.0 | 178.4 | 139.6 |
| 313T3 | 2 | 0 | 77.7 | 84.1 | 71.3 |
| 313T4 | 2 | 0 | 73.3 | 90.9 | 55.6 |
| 313T5 | 2 | 0 | 158.8 | 187.9 | 129.7 |

* Outliers are not included in N UL = upper limit LL = lower limit

Table 1c. Screening Results – Fluorescence Immunoassay Methods

| Specimen | N | Outliers* | Mean (EIU)**** | UL (95%) | LL (95%) |
|----------|---|-----------|----------------|----------|----------|
| 313T1 | 2 | 0 | 23.0 | 30.8 | 15.1 |
| 313T2 | 2 | 0 | 160.0 | 174.4 | 145.6 |
| 313T3 | 2 | 0 | 1.0 | 3.8 | 0.0 |
| 313T4 | 2 | 0 | 0.8 | 2.8 | 0.0 |
| 313T5 | 2 | 0 | 1.0 | 3.6 | 0.0 |

* Outliers are not included in N UL = upper limit LL = lower limit

** OD = Absorbance units

*** UA/mL = Arbitrary units/mL serum

**** EIU = Enzyme immunoassay units/mL serum

Table 2. Frequency Distribution of Participants' Interpretations*
SCREENING RESULTS

| Specimen | <i>Toxoplasma</i> antibody non-reactive | <i>Toxoplasma</i> antibody reactive |
|----------|---|-------------------------------------|
| 313T1 | 2 | 6 |
| 313T2 | 0 | 8 |
| 313T3 | 8 | 0 |
| 313T4 | 8 | 0 |
| 313T5 | 6 | 2 |

*All Methods

Table 3. Frequency Distribution of Participants' Interpretations*
CONFIRMATORY RESULTS

| Specimen | <i>Toxoplasma</i> antibody non-reactive | <i>Toxoplasma</i> antibody reactive |
|----------|---|-------------------------------------|
| 313T1 | 0 | 3 |
| 313T2 | 0 | 3 |
| 313T3 | 2 | 1 |
| 313T4 | 3 | 0 |
| 313T5 | 3 | 0 |

*All methods

This **NEWBORN SCREENING QUALITY ASSURANCE PROGRAM** report is an internal publication distributed to program participants and selected program colleagues. The laboratory quality assurance program is a project cosponsored by the **Centers for Disease Control and Prevention (CDC)** and the **Association of Public Health Laboratories**.

CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)
ATLANTA, GA 30341

Director

Thomas R. Frieden, M.D., M.P.H.

Acting Director

National Center for Environmental Health

Robin M. Ikeda, M.D., M.P.H., RADM, USPHS

Director

Division of Laboratory Sciences

James L. Pirkle, M.D., Ph.D.

Chief

Newborn Screening and Molecular Biology Branch

Carla Cuthbert, Ph.D.



Contributors: Barbara W. Adam
Paul Dantonio
Victor R. De Jesus, Ph.D.
Marie C. Earley, Ph.D.
Sharon Flores
Stephanie Foster
Elizabeth M. Hall
Christopher Haynes, Ph.D.
Sarah Klass
Francis Lee, Ph.D.
Lixia Li, Ph.D.
Timothy Lim, Ph.D.
Daniel Mandel, Ph.D.
Joanne Mei, Ph.D.
Nancy Meredith
Patrick Pickens
Kelsey Sheard
Jennifer Taylor, Ph.D.
Robert Vogt, Ph.D.
Irene Williams
Golriz Yazdanpanah
Hui Zhou, Ph.D.
Sherri Zobel

Production: Sarah Brown
Felicia Manning
Connie Singleton



ASSOCIATION OF PUBLIC HEALTH LABORATORIES
SILVER SPRING, MD 20910

President

Christine Bean, Ph.D., M.B.A., MT(ASCP)

Chairman, Newborn Screening and Genetics in Public Health Committee

Susan M. Tanksley, Ph.D.

Chairman, Newborn Screening Quality Assurance Quality Control Subcommittee

Patrick Hopkin, B.S.

INQUIRIES TO:

Irene Williams, Editor • Centers for Disease Control and Prevention (CDC)
Newborn Screening Quality Assurance Program • Mailstop F-43
4770 Buford Highway, N.E. • Atlanta, GA 30341-3724
Phone (770) 488-4582 • FAX (770) 488-4255 • E-mail: IWilliams1@cdc.gov